Javygtor Tablet
NDC Package 43598-096-04
Package Information
Javygtor (sapropterin dihydrochloride) tablets is a medication used along with diet changes for long-term treatment of a certain inherited disorder (phenylketonuria-PKU). This formulation utilizes a tablet delivery system. Marketed by Dr. Reddys Laboratories Inc, this product is identified by NDC 43598-096 and is authorized under FDA application ANDA207685.
Identification & Billing
- RxCUI: 1486687 - sapropterin dihydrochloride 100 MG Oral Tablet
- RxCUI: 1486687 - sapropterin dihydrochloride 100 MG Soluble Tablet
- RxCUI: 2612671 - JAVYGTOR 100 MG Oral Tablet
- RxCUI: 2612671 - sapropterin dihydrochloride 100 MG Oral Tablet [Javygtor]
- RxCUI: 2612671 - Javygtor 100 MG (equivalent to sapropterin 76.8 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43598 - Dr. Reddys Laboratories Inc
- 43598-096 - Javygtor
- 43598-096-04 - 120 TABLET in 1 BOTTLE
- 43598-096 - Javygtor
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (43598-096). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43598-096-04 identifies a specific commercial package of 120 tablet in 1 bottle of Javygtor, a human prescription drug labeled by Dr. Reddys Laboratories Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 120 billable units per package. This tablet is formulated for oral use and contains sapropterin dihydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dr. Reddys Laboratories Inc on October 03, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used along with diet changes for long-term treatment of a certain inherited disorder (phenylketonuria-PKU). It helps remove a certain chemical (phenylalanine) from the body. Too much phenylalanine in the body can cause brain damage.
How is this Dr. Reddys Laboratories Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43598009604. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.